HUTCHMED

London: Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreemen

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

Chi-Med Loan Facility

Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib

TR-1: Notification of major interests in shares

Interim Results for the Six Months Ended 30 June 2011

China Healthcare Division expands OTC drug distribution and marketing operations

Notice of Announcement of 2011 Interim Results

Blocklisting Six Monthly Return

TR-1: Notification of major interests in shares

Results of Annual General Meeting

TR-1: Notification of major interests in shares

2010 Annual Report and Notice of Annual General Meeting

Director's Shareholding

Final Results for the year ended 31 December 2010 Strong performance across all divisions.

Board Change

Appointment of UBS Limited as Joint Broker

Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer

Notice of Announcement of 2010 Final Results

Total Voting Rights

Blocklisting Six Monthly Return

Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline

China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture

Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline

Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China

Appointment of Joint Broker

Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Notice of Announcement of 2010 Interim Results

Total Voting Rights

Blocklisting Six Monthly Return

Director's Shareholding

TR-1: Notification of major interests in shares

Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer

Results of Annual General Meeting

Seven-year extension of IP protection for Chi-Med's main prescription drug

2009 Annual Report and Notice of Annual General Meeting

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

TR-1: Notification of Major Interests in Shares

Final Results for the year ended 31 December 2009

Notice of Announcement of 2009 Final Results

Total Voting Rights

Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue

Total Voting Rights

Blocklisting Six Monthly Return

TR-1 : Notification of Major Interests in Shares

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases